Patents Examined by Jim Ketter
  • Patent number: 9169312
    Abstract: The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: October 27, 2015
    Assignee: San Diego State University Research Foundation
    Inventor: Roland Wolkowicz
  • Patent number: 9157059
    Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: October 13, 2015
    Assignee: Corning Incorporated
    Inventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
  • Patent number: 9149506
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: October 6, 2015
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Tirtha Chakraborty, Antonin de Fougerolles
  • Patent number: 9139637
    Abstract: The present invention provides a genetic method of tethering polypeptides to the yeast cell wall in a form accessible for binding to macromolecules. Combining this method with fluorescence-activated cell sorting provides a means of selecting proteins with increased or decreased affinity for another molecule, altered specificity, or conditional binding. As one embodiment, attaching an scFv antibody fragment to the Aga2p agglutinin effectively mimics the cell surface display of antibodies by B cells in the immune system for affinity maturation in vivo. As another embodiment, T cell receptor mutants can be isolated by this method that are efficiently displayed on the yeast cell surface, providing a means of altering T cell receptor binding affinity and specificity by library screening.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: September 22, 2015
    Assignee: Board of Trustees of the University of Illinois
    Inventors: K. Dane Wittrup, David M. Kranz, Michele Kieke, Eric T. Boder
  • Patent number: 9139837
    Abstract: Provided is a gene that is useful for imparting hydrogen peroxide resistance to a microorganism. Also provided is a method for using the same. The hydrogen peroxide resistance-imparting gene encoding a protein selected from the following proteins (a) to (c): (a) a protein having the amino acid sequence of SEQ ID NO: 2; (b) a protein which has an amino acid sequence equivalent to the amino acid sequence of (a), except that one to several amino acid residues are deleted, substituted, or added, and which exhibits hydrogen peroxide resistance-imparting activity; and (c) a protein which has an amino acid sequence having an identity of 85% or higher to the amino acid sequence of (a), and which exhibits hydrogen peroxide resistance-imparting activity.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: September 22, 2015
    Assignee: KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Masaki Serata, Mayumi Kiwaki, Tohru Iino
  • Patent number: 9137975
    Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: September 22, 2015
    Assignee: Bell Biosystems, Inc.
    Inventors: Caleb B. Bell, III, Alexey Bazarov
  • Patent number: 9133523
    Abstract: The present invention encompasses compositions and methods for detecting cancer metastasis.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 15, 2015
    Assignee: Washington University
    Inventors: Anne M. Bowcock, J. William Harbour
  • Patent number: 9133493
    Abstract: The present invention relates to methods for mammalian cell culture. The methods make use of independent tyrosine and cystine feed streams.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: September 15, 2015
    Assignee: AMGEN INC.
    Inventors: Matthew I. Jerums, Amanda Kano, Henry Lin, Shun Luo, Jian Wu, Rebecca E. McCoy, Arvia E. Morris
  • Patent number: 9127246
    Abstract: A method for processing a fluid includes sparging a fluid within the compartment of a container with an initial gas so that the initial gas passes through a portion of the fluid to form a humid gas within the compartment. The humid gas is passed out of the compartment of the container and into a flexible condenser bag. The humid gas within the condenser bag is cooled so as to separate the humid gas within the condenser bag into a condensed fluid and a dehumidified gas. The condensed fluid and the dehumidified gas is then removed from the condenser bag.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: September 8, 2015
    Assignee: Life Technologies Corporation
    Inventors: Clinton C. Staheli, Nephi D. Jones, Michael E. Goodwin
  • Patent number: 9116144
    Abstract: A stimuli responsive nanofiber that includes a stimuli responsive polymer, such as a thermally responsive polymer, and a cross-linking agent having at least two latent reactive activatable groups. The nanofiber may also include a biologically active material or a functional polymer. The stimuli responsive nanofiber can be used to modify the surface of a substrate. When the nanofiber includes a thermally responsive polymer, the physical properties of the surface can be controlled by controlling the temperature of the system, thus controlling the ability of the surface to bind to a biologically active material of interest.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: August 25, 2015
    Assignee: INNOVATIVE SURFACE TECHNOLOGIES, INC.
    Inventors: Tahmina Naqvi, Jie Wen, Patrick Guire
  • Patent number: 9114113
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: August 25, 2015
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Tirtha Chakraborty, Antonin de Fougerolles
  • Patent number: 9115361
    Abstract: A method for using cloning vector plasmids to produce DNA molecules, such as transgenes, in a single cloning step. The transgenes can be used for the purpose of gene expression or analysis of gene expression. The plasmid cloning vectors are engineered to minimize the amount of manipulation of DNA fragment components by the end user of the vectors and the methods for their use. Transgenes produced using the invention may be used in a single organism, or in a variety of organisms including bacteria, yeast, mice, and other eukaryotes with little or no further modification.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: August 25, 2015
    Assignee: Intrexon Corporation
    Inventor: Thomas D. Reed
  • Patent number: 9107886
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: August 18, 2015
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Tirtha Chakraborty, Antonin de Fougerolles
  • Patent number: 9110079
    Abstract: A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: August 18, 2015
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON (HCL)
    Inventors: Marie-Angélique Cazalis, Alexandre Pachot, Sylvie Tissot, Guillaume Monneret
  • Patent number: 9109216
    Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: August 18, 2015
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9097715
    Abstract: A high sensitive and specific non-invasive bladder cancer diagnosis and/or prognosis method based on the detection and quantification of the gene expression of a combination of bladder tumor markers in bladder fluids is provided. A preferred combination of the markers consists of the combination of ANXA10, C14orf78, CTSE, CRH, IGF2, KLF9, KRT20, MAGEA3, POSTN, PPP1R14D, SLC1A6, TERT, ASAM and MCM10 genes.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: August 4, 2015
    Assignee: FINA BIOTECH, S.L.U.
    Inventors: Antonio Alcaraz Asensio, Lourdes Mengual Brichs, Moises Burset Albareda, Maria Jose Ribal Caparros, Elisabet Ars Criach
  • Patent number: 9095552
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: August 4, 2015
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Tirtha Chakraborty, Antonin de Fougerolles
  • Patent number: 9090863
    Abstract: Systems are provided for convenient and sterile isolation, collection, and seeding of cells onto a scaffold or tissue graft. The systems may be closed. Methods for use of the disclosed systems for isolation, collection and seeding of cells and generation of tissue engineered vascular grafts are also provided. The systems may be supplied in kits for efficient and expeditious use.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: July 28, 2015
    Assignees: PALL CORPORATION, YALE UNIVERSITY
    Inventors: Christopher Breuer, Edward L. Snyder, Keru O. Shafi, Martin A. Smith
  • Patent number: 9089604
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 28, 2015
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Tirtha Chakraborty, Antonin de Fougerolles, Ron Weiss
  • Patent number: 9091679
    Abstract: The invention relates to a method for stimulating antigen-specific T cell responses by using accelerated co-cultured dendritic cells, and to uses thereof, such as a method for diagnosing a disease and a method for producing isolated T cell clones displaying specific immunological properties.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: July 28, 2015
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Roberto Mallone, Emanuela Martinuzzi